500
Participants
Start Date
August 1, 2022
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2024
sunitinib or pazopanib
Single targeted therapy
PD-1 inhibitor combined with axitinib
targeted therapy combined with immunotherapy
RECRUITING
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai
Collaborators (1)
Ruijin Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
West China Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Fudan University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Second Affiliated Hospital of Nantong University
OTHER
Peking University First Hospital
OTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
OTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
Zhejiang University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Sir Run Run Shaw Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
The General Hospital of Eastern Theater Command
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
The First Affiliated Hospital of University of Science and Technology of China
OTHER
The Second Hospital of Anhui Medical University
OTHER
Tongji Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Peking Union Medical College Hospital
OTHER
The First Affiliated Hospital of Shanxi Medical University
OTHER
Shaanxi Provincial Cancer Hospital
OTHER
Changzhi Medical College
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Second Affiliated Hospital of Xi'an Jiaotong University
OTHER
The First Affiliated Hospital of Air Force Medicial University
OTHER
Tang-Du Hospital
OTHER
Quanzhou First Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
RenJi Hospital
OTHER